太平洋给予皓元医药买入评级：Q2收入超预期，利润强劲增长

Group 1 - The core viewpoint of the article is that Pacific Securities has issued a buy rating for Haoyuan Pharmaceutical (688131.SH) based on its strong business growth and expanding product range [1] Group 2 - Front-end business is experiencing rapid growth with a continuous expansion of product varieties [1] - Back-end business shows steady growth with a significant increase in orders on hand [1]